Hyperglycosylated hCG and Placenta Accreta Spectrum

Area of Science:

• Reproductive Medicine
• Maternal-Fetal Medicine
• Biochemistry

Background:

• Placenta accreta spectrum (PAS) is a severe obstetric complication.
• Accurate diagnosis of PAS is crucial for effective management.
• Human chorionic gonadotropin (hCG) is a key pregnancy hormone, with hyperglycosylated hCG (hCG-H) being a specific form.

Purpose of the Study:

• To investigate the association between hyperglycosylated hCG (hCG-H) and placenta accreta spectrum (PAS).
• To evaluate hCG-H as a potential biomarker for diagnosing PAS in the second and third trimesters of pregnancy.

Main Methods:

• A case-control study design was employed.
• Serum hCG-H levels were measured in 30 patients with confirmed PAS and 30 matched controls.
• Statistical analyses included comparisons of means, diagnostic accuracy metrics, and receiver operating characteristic (ROC) curve analysis.

Main Results:

• Mean hCG-H levels were significantly lower in the PAS group (7.8 ± 5.9 μg/L) compared to the control group (11.8 ± 8.8 μg/L).
• An optimal cut-point of ≤7.6 μg/L for hCG-H yielded a sensitivity of 66.7% and specificity of 69.7%.
• The area under the ROC curve was 0.68, indicating modest diagnostic capability.

Conclusions:

• Lower levels of hyperglycosylated hCG (hCG-H) are observed in the second and third trimesters of pregnancy in women with placenta accreta spectrum (PAS).
• hCG-H demonstrates limited utility as a standalone diagnostic test for PAS.
• Further research may explore combined biomarkers for improved PAS diagnosis.